Following the transfer of rights, TaiGen will hold exclusive rights for development, manufacture, commercialization and sub-licensing of nemonoxacin.
TaiGen originally licensed nemonoxacin product rights in ten Asian countries and worldwide development rights through Phase II from Procter & Gamble Pharmaceuticals, which was acquired by Warner Chilcott in October 2009.
In August 2010, Warner Chilcott regained all rights outside the TaiGen territories after TaiGen announced positive data for the drug candidate.
Nemonoxacin demonstrated effective eradication of MRSA and quinolone-resistant MRSA in two Phase II trials for community acquired pneumonia (CAP) and diabetic foot infection.